MCKESSON CORP

MCK 10-K · Q4 2026
API behind this page

MCK Q4 2026 request

Playground key active
Request URL /api/financials?ticker=MCK&year=2026&quarter=4
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q4 2026 Q4 2025 YoY
Revenue 96,295 90,823 +6.0%
Show Business Segments breakouts
Medical-Surgical Solutions · Operating Segments 2,868 2,853 +0.5%
North American Pharmaceutical · Operating Segments 79,120 76,943 +2.8%
Oncology & Multispecialty · Operating Segments 12,711 9,431 +34.8%
Prescription Technology Solutions · Operating Segments 1,495 1,339 +11.7%
Show Consolidation Items breakouts
Material Reconciling Items 101 257 -60.7%
Cost of Revenue -92,251 -87,184 -5.8%
Gross Profit 4,044 3,639 +11.1%
Selling, General & Administrative -1,796 -1,975 +9.1%
Gain Loss Related To Litigation Settlement 1 0 —
Restructuring Costs And Asset Impairment Charges -99 -73 -35.6%
Operating Expenses -1,894 -2,048 +7.5%
Operating Income 2,150 1,591 +35.1%
Non-Operating Income (Expense) 36 -31 +216.1%
Interest Expense -61 -45 -35.6%
Income Loss Including Portion Attributable To Noncontrolling Interest 2,125 1,515 +40.3%
Income Tax Expense (Benefit) -270 -209 -29.2%
Net Income 1,855 1,306 +42.0%
Net Income Loss Attributable To Noncontrolling Interest -173 -46 -276.1%
Show Ownership breakouts
ClarusONE Sourcing Services, Vantage Oncology and SCRI Oncology -45 -46 +2.2%
Net Income 1,682 1,260 +33.5%
EPS (Diluted) 13.65 9.92 +37.6%
EPS (Basic) 13.72 9.98 +37.5%
Wtd Avg Shares (Diluted) -0.4 -0.7 +42.9%
Wtd Avg Shares (Basic) -0.4 -0.8 +50.0%
Income Before Taxes 2,125 1,515 +40.3%
Comprehensive Income 1,840 1,317 +39.7%
Depreciation And Amortization 196 151 +29.8%
Show Business Segments breakouts
Medical-Surgical Solutions · Operating Segments 25 24 +4.2%
North American Pharmaceutical · Operating Segments 36 31 +16.1%
Oncology & Multispecialty · Operating Segments 64 36 +77.8%
Prescription Technology Solutions · Operating Segments 20 21 -4.8%
Show Consolidation Items breakouts
Corporate Non Segment 51 35 +45.7%
Material Reconciling Items 0 4 -100.0%

Balance Sheet

Balance Sheet
Metric Q4 2026 Q4 2025 YoY
Current Assets
Cash & Cash Equivalents 3,975 5,691 -30.2%
Receivables Net Current 27,985 25,643 +9.1%
Show Business Segments breakouts
North American Pharmaceutical · Investee 443 313 +41.5%
Inventory 24,207 23,001 +5.2%
Prepaid Expenses & Other Current Assets 1,043 1,063 -1.9%
Total Current Assets 57,210 55,398 +3.3%
Non-Current Assets
Property, Plant & Equipment 2,668 2,502 +6.6%
Operating Lease Right-of-Use Assets 2,058 1,782 +15.5%
Goodwill 11,316 10,022 +12.9%
Show Business Segments breakouts
Medical-Surgical Solutions · Operating Segments 2,507 2,507 0.0%
North American Pharmaceutical · Operating Segments 2,781 2,737 +1.6%
Oncology & Multispecialty · Operating Segments 3,963 2,724 +45.5%
Prescription Technology Solutions · Operating Segments 2,065 2,027 +1.9%
Intangible Assets 4,079 1,464 +178.6%
Show Finite Lived Intangible Assets By Major Class breakouts
Customer Relationships 760 825 -7.9%
Other Intangible Assets 95 4 +2275.0%
Provider networks 368 — —
Service Agreements 2,416 388 +522.7%
Technology Based Intangible Assets 157 147 +6.8%
Trademarks And Trade Names 283 100 +183.0%
Other Non-Current Assets 4,992 3,972 +25.7%
Total Assets 82,323 75,140 +9.6%
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 818 610 +34.1%
Deferred Tax Assets 432 367 +17.7%
Current Liabilities
Accounts Payable 59,973 55,330 +8.4%
Long Term Debt And Capital Lease Obligations Current 1,267 1,191 +6.4%
Operating Lease Liability Current 287 258 +11.2%
Accrued Liabilities 5,490 4,825 +13.8%
Total Current Liabilities 67,017 61,604 +8.8%
Non-Current Liabilities
Deferred Tax Liabilities 1,330 1,029 +29.3%
Operating Lease Liabilities 1,801 1,478 +21.9%
Litigation Reserve Noncurrent 5,091 5,601 -9.1%
Other Non-Current Liabilities 2,659 2,659 0.0%
Long-Term Debt 6,526 5,654 +15.4%
Show Fair Value Hierarchy breakouts
Fair Value Inputs Level2 6,526 5,654 +15.4%
Show Debt Instrument breakouts
1.30% Notes due August 15, 2026 · Loans Payable 500 499 +0.2%
1.63% Euro Notes due October 30, 2026 · Loans Payable 578 541 +6.8%
3.13% Sterling Notes due February 17, 2029 · Loans Payable 595 581 +2.4%
3.95% Notes due February 16, 2028 · Loans Payable 343 343 0.0%
4.25% Notes due September 15, 2029 · Loans Payable 500 500 0.0%
4.65% Notes due May 30, 2030 · Loans Payable 650 — —
4.75% Notes due May 30, 2029 · Loans Payable 196 196 0.0%
4.88% Notes due March 15, 2044 · Loans Payable 255 255 0.0%
4.90% Notes due July 15, 2028 · Loans Payable 400 399 +0.3%
4.95% Notes due May 30, 2032 · Loans Payable 650 — —
5.10% Notes due July 15, 2033 · Loans Payable 597 597 0.0%
5.25% Notes due May 30, 2035 · Loans Payable 699 — —
6.00% Notes due March 1, 2041 · Loans Payable 218 217 +0.5%
7.65% Debentures due March 1, 2027 · Loans Payable 150 150 0.0%
Show Long-Term Debt Type breakouts
Lease and other obligations 195 227 -14.1%
Total Liabilities (Q) — — —
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 287 47 +510.6%
Other Liabilities
Long Term Debt And Capital Lease Obligations 5,259 4,463 +17.8%
Redeemable Noncontrolling Interest Equity Common Carrying Amount 943 — —
Show Equity Components breakouts
Redeemable Noncontrolling Interests 943 — —
Stockholders' Equity
Common Stock 3 3 0.0%
Additional Paid-In Capital 8,284 8,373 -1.1%
Retained Earnings 22,291 17,921 +24.4%
Accumulated Other Comprehensive Income -745 -932 +20.1%
Treasury Stock Common Value -32,005 -27,439 -16.6%
Total Stockholders' Equity -2,172 -2,074 -4.7%
Minority Interest 395 380 +3.9%
Show Ownership breakouts
ClarusONE Sourcing Services, Vantage Oncology and SCRI Oncology 395 380 +3.9%
Stockholders Equity Including Portion Attributable To Noncontrolling Interest -1,777 -1,694 -4.9%
Show Equity Components breakouts
Accumulated Defined Benefit Plans Adjustment Net Gain Loss Including Portion Attributable To Noncontrolling Interest 16 14 +14.3%
Accumulated Foreign Currency Adjustment Including Portion Attributable To Noncontrolling Interest -708 -989 +28.4%
Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest 5 -4 +225.0%
Accumulated Other Comprehensive Income -745 -932 +20.1%
Additional Paid In Capital 8,284 8,373 -1.1%
Aoci Including Portion Attributable To Noncontrolling Interest -745 -932 +20.1%
Common Stock 3 3 0.0%
Noncontrolling Interest 395 380 +3.9%
Retained Earnings 22,291 17,921 +24.4%
Treasury Stock Common -32,005 -27,439 -16.6%
Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax -58 47 -223.4%
Total Liabilities & Equity 82,323 75,140 +9.6%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q4 2026 YTD Q4 2025 YoY
Operating Activities
Depreciation 67 60 +11.7%
Adjustment For Amortization 129 91 +41.8%
Other Asset Impairment Charges 45 15 +200.0%
Increase Decrease In Deferred Income Taxes 222 -260 +185.4%
Inventory L I F O Reserve Period Charge -182 -3 -5966.7%
Operating Lease Expense 77 66 +16.7%
Gain Loss On Sale Of Other Assets -488 -86 -467.4%
Provision For Doubtful Accounts 19 14 +35.7%
Other Non-Cash Items 93 213 -56.3%
Increase Decrease In Receivables 131 129 +1.6%
Change in Inventory 3,016 864 +249.1%
Change in Accounts Payable -574 5,624 -110.2%
Increase Decrease In Operating Lease Liability -68 -99 +31.3%
Increase Decrease In Accrued Taxes Payable -523 152 -444.1%
Increase Decrease In Litigation Reserve -15 -15 0.0%
Increase Decrease In Other Operating Capital Net -383 -323 -18.6%
Net Cash from Operations 3,421 7,748 -55.8%
Investing Activities
Capital Expenditures -111 -169 +34.3%
Payments To Acquire Software -74 -109 +32.1%
Payments To Acquire Businesses Net Of Cash Acquired -4 -21 +81.0%
Proceeds From Divestiture Of Businesses And Interests In Affiliates 693 96 +621.9%
Other Investing Activities -79 -21 -276.2%
Net Cash from Investing 425 -224 +289.7%
Financing Activities
Proceeds From Short Term Debt 6,972 3,691 +88.9%
Repayments Of Short Term Debt -6,972 -6,116 -14.0%
Proceeds From Issuance Of Long Term Debt 0 0 —
Repayments Of Long Term Debt -8 -9 +11.1%
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options 24 28 -14.3%
Share Repurchases -2,671 -300 -790.3%
Payments Of Dividends Common Stock -101 -91 -11.0%
Proceeds From Payments For Other Financing Activities -64 -58 -10.3%
Net Cash from Financing -2,820 -2,855 +1.2%
Supplemental
Restricted Cash Current -93 -265 +64.9%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents -11 5 -320.0%
Net Change in Cash 1,015 4,674 -78.3%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 4,068 5,956 -31.7%

Values in millions USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key